NASDAQ:EIGREiger Biopharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Eiger Biopharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $11.19 -0.11 (-0.97 %) (As of 08/5/2020 02:40 PM ET) Add Compare Share Today's Range$11.15Now: $11.19▼$11.6050-Day Range$9.30MA: $10.03▼$11.1552-Week Range$4.55Now: $11.19▼$15.82Volume4,656 shsAverage Volume464,781 shsMarket Capitalization$280.42 millionP/E RatioN/ADividend YieldN/ABeta1.47 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Eiger BioPharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare diseases in the United States and internationally. The company's lead program is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trial for treating hepatitis delta virus (HDV) infection. Its product candidates also include Lambda, which targets type III IFN receptors; Lonafarnib for the treatment of progeria and progeroid laminopathies; Avexitide for treating post-bariatric hypoglycemia; and Ubenimex, an oral, small-molecule inhibitor of leukotriene A4 hydrolase for treating lymphedema. The company was founded in 2008 and is headquartered in Palo Alto, California.Read More Beat the Market (BTM) Rank™ 3.3 Analyst's Opinion Consensus RatingEiger Biopharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $32.50, Eiger Biopharmaceuticals has a potential upside of 188.6% from its current price of $11.26.Amount of Analyst CoverageEiger Biopharmaceuticals has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Community Rank Outperform VotesEiger Biopharmaceuticals has received 404 “outperform” votes. (Add your “outperform” vote.)Underperform VotesEiger Biopharmaceuticals has received 279 “underperform” votes. (Add your “underperform” vote.)Community SentimentEiger Biopharmaceuticals has received 59.15% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Eiger Biopharmaceuticals and other stocks. Vote “Outperform” if you believe EIGR will outperform the S&P 500 over the long term. Vote “Underperform” if you believe EIGR will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldEiger Biopharmaceuticals does not currently pay a dividend.Dividend GrowthEiger Biopharmaceuticals does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Eiger Biopharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.50% of the stock of Eiger Biopharmaceuticals is held by insiders.Percentage Held by Institutions71.50% of the stock of Eiger Biopharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Eiger Biopharmaceuticals are expected to grow in the coming year, from ($1.65) to ($1.64) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Eiger Biopharmaceuticals is -3.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Eiger Biopharmaceuticals is -3.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEiger Biopharmaceuticals has a P/B Ratio of 4.87. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.3Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.59 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:EIGR Previous Symbol CUSIPN/A CIK1305253 Webwww.eigerbio.com Phone650-272-6138Debt Debt-to-Equity Ratio0.74 Current Ratio6.14 Quick Ratio6.14Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.31 per share Price / Book4.84Profitability EPS (Most Recent Fiscal Year)($3.08) Net Income$-70,250,000.00 Net MarginsN/A Return on Equity-105.31% Return on Assets-61.19%Miscellaneous Employees18 Outstanding Shares25,060,000Market Cap$280.42 million Next Earnings Date8/13/2020 (Estimated) OptionableNot Optionable $11.19 -0.11 (-0.97 %) (As of 08/5/2020 02:40 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive EIGR News and Ratings via Email Sign-up to receive the latest news and ratings for EIGR and its competitors with MarketBeat's FREE daily newsletter. Eiger Biopharmaceuticals (NASDAQ:EIGR) Frequently Asked Questions How has Eiger Biopharmaceuticals' stock been impacted by COVID-19 (Coronavirus)? Eiger Biopharmaceuticals' stock was trading at $6.81 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, EIGR shares have increased by 64.3% and is now trading at $11.19. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Eiger Biopharmaceuticals? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eiger Biopharmaceuticals in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Eiger Biopharmaceuticals. When is Eiger Biopharmaceuticals' next earnings date? Eiger Biopharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Eiger Biopharmaceuticals. How were Eiger Biopharmaceuticals' earnings last quarter? Eiger Biopharmaceuticals Inc (NASDAQ:EIGR) announced its quarterly earnings results on Thursday, May, 7th. The biotechnology company reported ($0.62) EPS for the quarter, beating the consensus estimate of ($0.76) by $0.14. View Eiger Biopharmaceuticals' earnings history. What price target have analysts set for EIGR? 3 brokerages have issued twelve-month target prices for Eiger Biopharmaceuticals' shares. Their forecasts range from $31.00 to $34.00. On average, they anticipate Eiger Biopharmaceuticals' share price to reach $32.50 in the next twelve months. This suggests a possible upside of 190.4% from the stock's current price. View analysts' price targets for Eiger Biopharmaceuticals. What are Wall Street analysts saying about Eiger Biopharmaceuticals stock? Here are some recent quotes from research analysts about Eiger Biopharmaceuticals stock: 1. According to Zacks Investment Research, "Eiger BioPharmaceuticals, Inc. is a biopharmaceutical company which develops and manufactures drugs and therapies for the treatment of orphan diseases. Eiger BioPharmaceuticals, Inc., formerly known as Celladon Corporation, is based in Palo Alto, California. " (8/4/2020) 2. LADENBURG THALM/SH SH analysts commented, "We believe its cash is sufficient to fund operations through profitability in 2022, assuming it nets ~$50M for its after splitting it with the Progeria Research Foundation. While the last four months the news flow from Eiger’s HDV and progeria programs has been quiet, the next four months include several catalysts in these programs." (8/12/2019) Has Eiger Biopharmaceuticals been receiving favorable news coverage? Media coverage about EIGR stock has been trending somewhat negative on Wednesday, according to InfoTrie. The research firm identifies positive and negative press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Eiger Biopharmaceuticals earned a news sentiment score of -1.0 on InfoTrie's scale. They also gave press coverage about the biotechnology company a news buzz of 5.0 out of 10, meaning that recent press coverage is somewhat likely to have an impact on the company's share price in the next few days. View the latest news about Eiger Biopharmaceuticals. Are investors shorting Eiger Biopharmaceuticals? Eiger Biopharmaceuticals saw a drop in short interest in the month of July. As of July 15th, there was short interest totaling 604,500 shares, a drop of 12.4% from the June 30th total of 690,000 shares. Based on an average daily trading volume, of 414,100 shares, the short-interest ratio is currently 1.5 days. Approximately 2.7% of the shares of the company are sold short. View Eiger Biopharmaceuticals' Current Options Chain. Who are some of Eiger Biopharmaceuticals' key competitors? Some companies that are related to Eiger Biopharmaceuticals include Adaptimmune Therapeutics (ADAP), Vaxart (VXRT), Compugen (CGEN), Beam Therapeutics (BEAM), Nantkwest (NK), I-Mab (BDTX), Translate Bio (TBIO), BAVARIAN NORDIC/S (BVNRY), Replimune Group (REPL), Poseida Therapeutics (PSTX), Vericel (VCEL), Atara Biotherapeutics (ATRA), BioCryst Pharmaceuticals (BCRX), Cellectis (CLLS) and Krystal Biotech (KRYS). View all competitors. What other stocks do shareholders of Eiger Biopharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Eiger Biopharmaceuticals investors own include Achillion Pharmaceuticals (ACHN), Skyworks Solutions (SWKS), ZIOPHARM Oncology (ZIOP), Amarin (AMRN), Celldex Therapeutics (CLDX), Gilead Sciences (GILD), Progenics Pharmaceuticals (PGNX), Bausch Health Companies (BHC), Catalyst Pharmaceuticals (CPRX) and Exelixis (EXEL). Who are Eiger Biopharmaceuticals' key executives? Eiger Biopharmaceuticals' management team includes the following people: Mr. David A. Cory R.Ph, MBA, Bus. Founder, Pres, CEO & Director (Age 55)Dr. Jeffrey S. Glenn, Founder, Scientific Advisor & Director (Age 56)Dr. David Apelian, COO, Exec. Medical Officer & Director (Age 54)Mr. James P. Shaffer, Chief Bus. Officer (Age 52)Mr. Sriram Ryali M.B.A., Chief Financial Officer (Age 38) What is Eiger Biopharmaceuticals' stock symbol? Eiger Biopharmaceuticals trades on the NASDAQ under the ticker symbol "EIGR." Who are Eiger Biopharmaceuticals' major shareholders? Eiger Biopharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include P.A.W. Capital Corp (1.20%), DAVENPORT & Co LLC (0.97%), UBS Group AG (0.36%), Assenagon Asset Management S.A. (0.26%), Russell Investments Group Ltd. (0.10%) and Wedbush Securities Inc. (0.09%). Company insiders that own Eiger Biopharmaceuticals stock include David A Cory, Eldon C Mayer III, Interwest Partners X Lp, Sriram Ryali, Stephana Eilene Patton and Thomas John Dietz. View institutional ownership trends for Eiger Biopharmaceuticals. Which major investors are selling Eiger Biopharmaceuticals stock? EIGR stock was sold by a variety of institutional investors in the last quarter, including P.A.W. Capital Corp, and DAVENPORT & Co LLC. View insider buying and selling activity for Eiger Biopharmaceuticals. Which major investors are buying Eiger Biopharmaceuticals stock? EIGR stock was purchased by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., UBS Group AG, SG Americas Securities LLC, Russell Investments Group Ltd., and Wedbush Securities Inc.. Company insiders that have bought Eiger Biopharmaceuticals stock in the last two years include David A Cory, Eldon C Mayer III, Sriram Ryali, Stephana Eilene Patton, and Thomas John Dietz. View insider buying and selling activity for Eiger Biopharmaceuticals. How do I buy shares of Eiger Biopharmaceuticals? Shares of EIGR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Eiger Biopharmaceuticals' stock price today? One share of EIGR stock can currently be purchased for approximately $11.19. How big of a company is Eiger Biopharmaceuticals? Eiger Biopharmaceuticals has a market capitalization of $280.42 million. The biotechnology company earns $-70,250,000.00 in net income (profit) each year or ($3.08) on an earnings per share basis. Eiger Biopharmaceuticals employs 18 workers across the globe. What is Eiger Biopharmaceuticals' official website? The official website for Eiger Biopharmaceuticals is www.eigerbio.com. How can I contact Eiger Biopharmaceuticals? Eiger Biopharmaceuticals' mailing address is 2155 PARK BOULEVARD, PALO ALTO CA, 94306. The biotechnology company can be reached via phone at 650-272-6138 or via email at [email protected] This page was last updated on 8/5/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
